US · MRNA
Moderna, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02139
- Website
- modernatx.com
Price · as of 2025-12-31
$45.37
Market cap 20.93B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $32.76 | -27.79% |
| Intrinsic Value(DCF) | $25.62 | -43.53% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $213.03 | +369.54% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $20.93 | $32.92 | $2.75 | $0.00 | $28.99 |
| 2019 | $29.61 | $36.52 | $1.58 | $0.00 | $69.71 |
| 2020 | $136.99 | $253.02 | $7,937.89 | $0.00 | $0.00 |
| 2021 | $138.20 | $710.14 | $5,218,546.45 | $186.49 | $61,285.40 |
| 2022 | $138.29 | $216.81 | $96,038.82 | $154.65 | $302.48 |
| 2023 | $103.03 | $49.13 | $5.29 | $0.00 | $652.75 |
| 2024 | $35.61 | $18.74 | $8.39 | $0.00 | $396.50 |
| 2025 | $52.85 | $32.76 | $7.70 | $0.00 | $213.03 |
AI valuation
Our deep-learning model estimates Moderna, Inc.'s (MRNA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $32.76
- Current price
- $45.37
- AI upside
- -27.79%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$25.62
-43.53% upside
Graham-Dodd
—
— upside
Graham Formula
$213.03
+369.54% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MRNA | Moderna, Inc. | $45.37 | 20.93B | -28% | -44% | — | +370% | -7.28 | 2.38 | 10.57 | -6.53 | — | 2.38 | 55.35% | -158.13% | -145.16% | -28.87% | -65.47% | -21.31% | 0.22 | — | 3.29 | 3.01 | 0.27 | -2168.00% | -3923.00% | -4908.00% | -10.05% | -0.94 | -43.98% | 0.00% | 0.00% | 0.00% | -5.42 | -8.07 | 8.58 | 3.94 |
| BBIO | BridgeBio Pharma, Inc. | $66.48 | 12.89B | -12% | +7,582% | — | — | -17.82 | -6.22 | 25.73 | -22.38 | -56.40 | -6.14 | 94.37% | -113.35% | -145.26% | 40.90% | 321.74% | -78.14% | -1.31 | -10.72 | 2.62 | 2.52 | -3.21 | 3160.00% | 12626.00% | -1431.00% | -3.46% | -1.55 | 252.72% | 0.00% | 0.00% | 0.37% | -26.46 | -33.69 | 30.00 | -4.02 |
| BMRN | BioMarin Pharmaceutical I… | $61.73 | 11.86B | +37% | -52% | -36% | -40% | 32.84 | 1.88 | 3.56 | 18.32 | — | 2.02 | 77.13% | 16.56% | 10.83% | 5.94% | 7.50% | 4.79% | 0.10 | 48.95 | 5.21 | 3.25 | -1.25 | -1855.00% | 1287.00% | 5249.00% | 6.33% | 1.09 | 14.09% | 0.00% | 0.00% | 3.68% | 19.67 | 14.48 | 3.26 | 5.75 |
| CAI | Caris Life Sciences, Inc. | $20.14 | 5.68B | +132% | +659% | — | — | -507.35 | 59.84 | 42.54 | 2965.27 | — | 61.91 | 66.40% | 5.56% | -66.25% | 7.09% | -3.82% | -9.27% | 0.00 | 0.79 | 7.85 | 7.17 | -70.09 | -2963.00% | 9697.00% | -12637.00% | 0.19% | 0.65 | -5.66% | 0.00% | 0.00% | 3.35% | 748.01 | 504.44 | 41.56 | 36.41 |
| EXEL | Exelixis, Inc. | $44.06 | 11.81B | +59% | -51% | -50% | -3% | 14.24 | 5.16 | 4.80 | 11.13 | 24.57 | 5.31 | 96.39% | 37.59% | 33.73% | 35.53% | 55.80% | 27.02% | 0.08 | — | 3.56 | 3.32 | -0.34 | 5795.00% | 698.00% | 3322.00% | 7.58% | 2.18 | 64.97% | 0.00% | 0.00% | 11.04% | 11.76 | 12.15 | 4.42 | 12.01 |
| HALO | Halozyme Therapeutics, In… | $69.53 | 8.21B | +26% | +70% | -87% | +68% | 26.42 | 171.48 | 5.99 | 9.10 | — | -5.53 | 78.13% | 58.45% | 22.69% | 153.59% | 93.94% | 13.81% | 0.00 | 45.03 | 4.66 | 3.30 | -0.15 | -2536.00% | 3755.00% | 3762.00% | 7.70% | 3.68 | 109.29% | 0.00% | 0.00% | 22.29% | 10.08 | 12.76 | 5.89 | 3.99 |
| JAZZ | Jazz Pharmaceuticals plc | $190.02 | 11.7B | -5% | -56% | -94% | — | -32.61 | 2.69 | 2.72 | 104.22 | — | -5.99 | 88.21% | 5.26% | -8.35% | -8.47% | 2.26% | -3.01% | 0.25 | 1.15 | 1.86 | 0.99 | -2.87 | -16751.00% | 488.00% | -377.00% | 11.17% | 0.60 | 23.02% | 0.00% | 0.00% | 36.04% | 50.37 | 8.72 | 2.65 | 1.65 |
| MDGL | Madrigal Pharmaceuticals,… | $432.00 | 9.81B | -42% | +134,896% | — | — | -33.90 | 16.22 | 10.20 | -34.57 | — | 16.42 | 94.14% | -31.31% | -30.08% | -42.49% | 761.60% | -25.05% | 0.59 | -13.45 | 4.01 | 3.60 | -0.59 | -4132.00% | 43205.00% | -5842.00% | -1.94% | -0.61 | 482.24% | 0.00% | 0.00% | 0.00% | -30.47 | -48.12 | 9.54 | 7.47 |
| RNA | Avidity Biosciences, Inc. | $14.75 | 2.28B | +47% | -35% | — | — | -3.00 | 1.22 | 109.48 | -0.66 | -4.17 | 1.22 | 77.87% | -3977.30% | -3650.39% | -43.98% | -9010.06% | -38.88% | 0.06 | — | 9.20 | 8.75 | 0.42 | 7197.00% | 7211.00% | 11555.00% | -32.33% | -3.33 | -8017.39% | 0.00% | 0.00% | 3.65% | -0.60 | -0.68 | 24.04 | 3.18 |
| RVMD | Revolution Medicines, Inc… | $102.02 | 19.72B | — | — | — | — | -17.08 | 11.84 | — | -16.01 | -25.80 | 12.38 | 0.00% | — | — | -58.07% | 1908.09% | -46.06% | 0.10 | -48.80 | 7.14 | 6.97 | 0.21 | 6620.00% | — | 6094.00% | -4.73% | -3.09 | 1474.57% | 0.00% | 0.00% | 0.00% | -14.76 | -19.10 | — | 13.58 |
| TECH | Bio-Techne Corporation | $59.00 | 9.23B | -19% | -63% | -94% | -90% | 116.45 | 4.45 | 7.01 | 40.71 | — | 14.94 | 64.80% | 8.38% | 6.02% | 3.68% | 3.36% | 2.79% | 0.23 | 12.02 | 3.46 | 2.10 | 1.30 | -5619.00% | 523.00% | 866.00% | 3.00% | 1.64 | 11.31% | 0.59% | 68.70% | 3.82% | 86.35 | 34.42 | 7.24 | 9.42 |
About Moderna, Inc.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
- CEO
- Stéphane Bancel
- Employees
- 5.8K
- Beta
- 1.34
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($25.62 ÷ $45.37) − 1 = -43.53% (DCF, example).